Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neumega recombinant human interleukin-11 data

Evaluation of the first 12 patients in a Phase I trial of rhIL-11indicated the agent was able to

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE